Company news

CNS Pharmaceuticals, Inc. news in 2022

CNS Pharmaceuticals, Inc.'s news releases, calls and decks from 2022, newest first.

View company

CNS Pharmaceuticals Announces Preliminary Results from Ongoing Potentially Pivotal Trial Evaluating Berubicin for the Treatment of Recurrent Glioblastoma Multiforme (GBM)

December 7, 2022

CNS Pharmaceuticals to Participate at the Virtual Investor "Ask the CEO" Event

December 4, 2022

CNS Pharmaceuticals Announces Pricing of $6.0 Million Public Offering At a Premium to the Market Closing Price

November 29, 2022

CNS Pharmaceuticals Reports Third Quarter 2022 Financial Results and Provides Corporate Update

November 13, 2022

CNS Pharmaceuticals Announces Dosing of First Patient in Europe/France in Ongoing Potentially Pivotal Global Trial Evaluating Berubicin for the Treatment of GBM

November 1, 2022

CNS Pharmaceuticals to Participate in The American Brain Tumor Association's Breakthrough (ABTA) for Brain Tumors® 5K (BT5K) Run

October 9, 2022

CNS Pharmaceuticals Announces Activation of First Clinical Trial Sites in Europe for Ongoing Potentially Pivotal Global Trial Evaluating Berubicin for the Treatment of GBM

September 27, 2022

CNS Pharmaceuticals Reports Second Quarter 2022 Financial Results and Provides Corporate Update

August 14, 2022

CNS Pharmaceuticals Urges Shareholders to Vote in Favor of Proxy Proposals for the Upcoming Annual Meeting of Shareholders on July 27, 2022

July 24, 2022

CNS Pharmaceuticals Receives Approval from U.S. FDA for Protocol Amendment to Ongoing Potentially Pivotal Global Trial Evaluating Berubicin for the Treatment of GBM

June 22, 2022

CNS Pharmaceuticals Announces Presentation of Ongoing Potentially Pivotal Berubicin Clinical Trial Design at the American Society of Clinical Oncology (ASCO) 2022 Annual Meeting

June 7, 2022

CNS Pharmaceuticals Announces Acceptance of Abstract for Poster Presentation at the American Society of Clinical Oncology (ASCO) 2022 Annual Meeting

May 17, 2022

CNS Pharmaceuticals Reports First Quarter 2022 Financial Results and Provides Corporate Update

May 15, 2022

CNS Pharmaceuticals Receives Approval from Ethics Committee and Competent Authority in Spain for Potentially Pivotal Study of Berubicin for the Treatment of Glioblastoma Multiforme (GBM)

April 27, 2022

CNS Pharmaceuticals Receives Approval from France Ethics Committee and Competent Authority for Potentially Pivotal Study of Berubicin for the Treatment of Glioblastoma Multiforme (GBM)

April 5, 2022

CNS Pharmaceuticals Receives Approval from Competent Authority of Switzerland for Potentially Pivotal Study of Berubicin for the Treatment of Glioblastoma Multiforme (GBM)

April 4, 2022

CNS Pharmaceuticals Reports Full Year 2021 Financial Results and Provides Corporate Update

March 2, 2022

CNS Pharmaceuticals Announces Closing of $11.5 Million Private Placement Priced At-the-Market Under Nasdaq Rules

January 9, 2022

CNS Pharmaceuticals Announces $11.5 Million Private Placement Priced At-the-Market Under Nasdaq Rules

January 5, 2022

Decks in 2022